Search This Blog

Wednesday, March 2, 2022

70% Of Russian Crude Trade Is Frozen As Surgut Again Fails To Sell Any Urals In Big Tenders

 As discussed yesterday in "Buyers Balk At Russian Oil Purchases Despite Record Discounts, Sanction Carve Outs" the bevy of Russian sanctions have had the unintended consequence of also freezing Russian oil exports - despite explicit carve outs in terms set by Western nations - as buyers balk and boycott Russian crude sales amid fears that the country's energy supplies may eventually fall under a sanctions regime anyway, leaving buyers stuck with millions in barrels they can't then sell to downstream clients.

Today was a clear example of just that: citing traders with knowledge of tenders, Bloomberg reported that Surgutneftegaz (better known as Surgut) failed to award two tenders with combined volume of 880k tons of Urals for March loading.

This was the third time that Surgut failed to sell any of the crude it was offering, "highlighting the difficulty for Russian producers to find buyers after the nation’s invasion into Ukraine."

In a separate, smaller tender, Surgut was offering 8 cargoes of 100k tons each from Baltic ports, and another 80k tons cargo from Black Sea in a separate tender. It was unclear if any bidders stepped up for those.

Of course, the longer Russia, and its roughly 6 mm barrels in daily oil exports remain stuck, the greater the cumulative price shock will be. Commenting on this, Bloomberg's Alaric Nightingale said that there’s a clear and obvious short-term supply shock for Russian oil and that’s why prices are marching ever higher, having hit a decade high of $114 earlier today before stabilizing around $110.

As Nightingale continues, "tanker companies don’t want to take it and refineries are looking elsewhere. There is a huge risk in being involved in Russian barrels.  Imagine you are a trader of Russian crude. You have to get the barrels and freight cheap enough, and then you have to know you have an end buyer who’ll take the cargo no matter what. Some tanker owners will go at the right price, some won’t. Some refineries are already voting with their feet." 

In short, there is a sense across the petroleum supply chain that sanctions aren’t done yet or aren’t well-enough understood yet. That’s why things are getting blocked. 

Meanwhile, Energy Aspects estimates that 70% of Russia’s crude trade is frozen but that will drop to 20% when there’s greater visibility on sanctions.

While that’s a reasonable proposition but there is an x-factor: could the final sanctions package actually be even more punitive for the country’s exports? Even if 20% were to end up frozen, that would still be a very bullish final scenario for the oil market; as a reminder, Goldman recently noted that even assuming full Russian output, the market remains undersupplied and continued disruptions will push oil much higher.

So what does the market think? Well, the 10x increase in Brent $200 June calls in the past week should give you a sense of what may be coming.

https://www.zerohedge.com/crypto/70-russian-crude-trade-frozen-surgut-again-fails-sell-any-urals-big-tenders

SAB: NIH Discontinuing Phase 3 for Treatment of COVID-19 Due to Declining COVID Hospitalizations

 

  • NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable
  • SAB-185 had advanced into Phase 3 after meeting pre-specified efficacy and safety criteria
  • SAB-185’s targeted, highly potent, fully human polyclonal antibodies have demonstrated neutralization of multiple SARS-CoV-2 variants in vitro, including Delta and Omicron
  • SAB is evaluating future clinical plans for SAB-185 including potential targeted applications such as prophylaxis and treatment in high-risk patient groups

COVID-19, Manufacturing Challenges Trip up Finch's C. Difficile Trial

 The US Food and Drug Administration has issued a clinical hold letter regarding Finch Therapeutics' Phase III PRISM4 trial, requiring the company to submit additional information on its screening protocols.

The letter, dated February 24, 2022, asked Finch to pause enrollment for the trial on CP101 in recurrent C. difficile infection, pending details on how SARS-CoV-2 donor samples will be shipped to the vendor that will perform the testing, as well as how they would handle inconclusive results. 

Finch said it would cooperate closely with the FDA and provide all the needed data to lift the hold order as soon as possible. As of this writing, the company is still evaluating how the hold will affect the trial's timeline. The letter also reportedly only mentioned the lack of data and did not say anything about adverse reactions experienced during the trial. 

In March 2020, the FDA had issued a warning on the possible risk of SARS-CoV-2 transmission in donor-derived investigational trials and called on companies to implement extra precautionary measures to prevent this. 

At the time, Finch's investigational new drug application for CP101 was placed on partial clinical hold, alongside then-contract manufacturer OpenBiome, requiring the implementation of safety protocols for data collected on or after December 1, 2019. Despite the partial hold notice, Finch was still able to continue dosing patients in its then-active PRISM-EXT Phase II study of CP101 because all of the data used in this study were taken before the December 1 cutoff. 

In January 2021, the hold on OpenBiome was lifted after it solved the issue using a direct-testing method via a third party provider. Finch then began dosing participants in the PRISM4 trial in November 2021. However, the latest FDA letter also notified Finch that the regulator would conduct a review of the trial's processes after Finch said it was dosing patients under the PRISM4 study while the hold was already in effect. 

Finch is largely known for its Human-First Discovery platform, which aims to develop a new class of orally administered biological medications to address a wide range of unmet medical needs. CP101, its lead candidate, managed to meet its primary efficacy endpoint in the PRISM3 trial in June 2020. 

The PRISM4 study is the second pivotal trial of the drug for recurrent CDI. The company is also developing CP101 for chronic hepatitis B and another product called FIN-211 for behavioral and gastrointestinal symptoms in children diagnosed with an autism spectrum disorder. 

News of the FDA's hold letter comes just a few weeks after the company appointed new members of its leadership team, namely Bryan Gillis, MBA as chief technology officer, Alka Batycky, Ph.D., as chief development officer and Howard Franklin, MD, MBA as senior vice president for the late-stage development and GI therapeutic unit. 

https://www.biospace.com/article/finch-pauses-phase-iii-prism-4-trial-after-fda-requests-more-data/

FDA slaps hold on Celyad phase 1 colorectal cancer trial

 

  • The FDA has issued a clinical hold on Celyad Oncology SA's  (Get Free Alerts for CYAD) CYAD-101-002 (KEYNOTE-B79) Phase 1b trial due to insufficient information to assess risk to study subjects.
  • As previously disclosed, the Company announced that it was voluntarily pausing the CYAD-101-002 trial to investigate reports of two fatalities in the study.
  • Celyad Oncology is a clinical-stage biotechnology company focused on discovering and developing chimeric antigen receptor T cell (CAR T) therapies for cancer. 
  • The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for hematological malignancies and solid tumors.

Inovio Covid vax candidate weaker against omicron

 Tucked in the Q4 earnings release, Inovio Pharmaceuticals Inc 

 (Get Free Alerts for INO) has paused enrollment for an ongoing INNOVATE Phase 3 trial of its lead COVID-19 vaccine candidate.

  • The decision follows as the shot showed significantly lower antibody levels against the omicron variant in lab testing.
  • The vaccine, INO-4800, maintained a robust T-cell response in the lab tests, leading Inovio to plan changes to the trial design.
  • T-cells are a vital part of the immune system's second line of defense.
  • The Company plans to seek regulatory approval to change the study's main goal to "prevention of severe disease due to COVID-19" from the earlier goal of "prevention of virologically confirmed COVID-19 disease."
  • An independent data safety monitoring board recommended that Inovio pause enrollment to reflect Omicron's potential impact on the trial. 
  • As a result, interim efficacy data from the trial will not be available in 1H of 2022 as previously expected.
  • In November, Inovio resumed the late-stage trial of its vaccine in the U.S. after 14 months on clinical hold.
  • The FDA in September 2020 put the study on hold as it sought more information, including details on a delivery device used to inject genetic material into cells.
  • Inovio held $401.3 million in cash and cash equivalents and short-term investments at the end of 2021.

Sorrento to Proceed With Phase 1 for Intranasal STI-9199 (COVISHIELD) Antibody

 

  • FDA granted IND clearance today for STI-9199 (COVISHIELD) for a Phase 1 safety and pharmacokinetic study in healthy volunteers.

  • Initial trials are expected to be followed by a multinational Phase 2/3 trial in both mild and moderate COVID-19 patients.

  • STI-9199 has demonstrated in vitro and in vivo activity against all SARS-CoV-2 variants tested, including the Omicron strain BA.1, Omicron BA.1+R346K and Omicron BA.2.

WTI Extends Gains After Cushing Stocks Drop Near 'Tank Bottoms', Crude Draws

 Oil prices are significantly higher this morning from yesterday's settlement, with WTI around $109 (having topped $112 earlier), as the market shrugs off Biden's plans to release some of the SPR, focusing still on geopolitical risk premia (and the fact that Russia's supply has been implicitly cut from the market as the tender for Urals crude received no bids this morning - it seems buyers are afraid of the potential for forthcoming sanctions to impact any purchases made now).

OPEC+ stuck to its plan this morning to increase production by 400k bbl/day:

“The situation in energy markets is very serious and demands our full attention,” IEA Executive Director Fatih Birol said in a statement. “Global energy security is under threat, putting the world economy at risk during a fragile stage of the recovery.”

For now, all eyes will be on the official data to see if API's big crude draw is confirmed...

API

  • Crude -6.1mm (+2.8mm exp) - biggest draw since September

  • Cushing -1mm

  • Gasoline -2.5mm

  • Distillates +0.4mm

DOE

  • Crude -2.597mm (+2.8mm exp)

  • Cushing -972k

  • Gasoline -468k

  • Distillates -574k

Draws across the board. Cushing stocks fell for the 8th straight week and crude inventories confirmed API's report with a sizable (though smaller than API) draw against expectations of a build...

Source: Bloomberg

This pushes Cushing stocks ever nearer operational lows as 'tank bottoms' are in sight...

Source: Bloomberg

US crude production was unchanged despite fresh urgings from the Biden admin and rising rig counts...

Source: Bloomberg

WTI was hovering around $109 ahead of the official data.

Perhaps unsurprisingly, crude imports from Russia last week dropped to zero.

We had three consecutive weeks of zero crude imports from Russia in Jan. Traders have said there is little evidence of new bookings. So far in 2022, Russian crude flows to the U.S. are on track for the slowest annual pace since 2017, according to data from Kpler.

Bloomberg Intelligence Energy Analyst Fernando Valle:

A potential coordinated release of global oil stockpiles, including a possible 60 million-barrel sale from the U.S. Strategic Petroleum Reserve, may not do much to stop the surge in prices for WTI and Brent crude, only decelerate the advance. The threat that financial sanctions against Russia for its invasion of Ukraine may limit movement for Urals crude is behind the rise, even though energy exports aren’t specifically targeted. Urals crude is unlikely to be replaced in the short run, as U.S. shale producers have already winnowed their inventories of drilled but uncompleted wells in recent months. Labor and equipment shortages may limit producers’ ability to raise output in 1H.

Meanwhile, the market's tightness is evident in the extreme backwardation in WTI - a record $20 spread from M1 to M6...

Source: Bloomberg

And right now, we are staring $4 gas national average in the face...

Source: Bloomberg

This is - in a very uncomfortable way - good news, since demand destruction tends to occur once gas pump prices top $3... and topping $4 will severely crimp demand.

And here - in one simple chart - is why the market is ignoring the SPR release - prices have exploded higher as SPR levels have plunged for two years...

Source: Bloomberg

So The Fed will be hiking into a recession!

https://www.zerohedge.com/energy/wti-extends-gains-after-cushing-stocks-drop-near-tank-bottoms-crude-draws